ABT-751 With Chemotherapy for Relapsed Pediatric ALL
Status:
Terminated
Trial end date:
2009-09-23
Target enrollment:
Participant gender:
Summary
This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott
Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic
leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done
to find the highest dose of ABT-751 that can be given safely in combination with other
chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects.
After a safe dose for ABT-751 given with chemotherapy has been found, the study will add
additional patients to find out if ABT-751 (given at the maximal safe dose) when given with
additional chemotherapy is an effective therapy for the treatment of children with relapsed
ALL. It is expected that approximately 15-35 children and young adults will take part in this
study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium